Literature DB >> 18715217

Prevalence of albuminuria and cardiovascular risk profile in a referred cohort of patients with type 2 diabetes: an Asian perspective.

C Y Pan1, L T Ho, S Soegondo, W Prodjosudjadi, S Suwanwalaikorn, S C Lim, T M Chan, K W Steven Chow, M Thoenes, D S Choi.   

Abstract

BACKGROUND: Microalbuminuria (MA) is a risk marker for diabetic nephropathy and cardiovascular (CV) disease (CVD) in patients with diabetes. This study aimed to describe the prevalence of albuminuria, CV risk factors, and treatments for renal and CV protection in an Asian population with type 2 diabetes.
METHODS: This cross-sectional study conducted in eight Asian countries enrolled normotensive/hypertensive adults with type 2 diabetes without known proteinuria and/or non-diabetic kidney disease. Exclusion criteria were type 1 diabetes, menstruation, pregnancy, and acute fever. A single random urinary albumin/creatinine test was carried out in all patients.
RESULTS: Of 8,561 patients, 14% had diabetic retinopathy, and 17% and 21% had history of CV disease and smoking, respectively. Normoalbuminuria was seen in 44%, MA in 44%, and macroalbuminuria in 12%. Target glycosylated hemoglobin (HbA1c) (<7%) was reached in only 37% of 3,834 patients with available values. Diabetes was managed by diet alone in 6%, while others received oral hypoglycemic drugs and/or insulin. In total, 75% did not reach target blood pressure (BP) of <or=130/80 mm Hg. Antihypertensive drugs were prescribed to 52%, with the number of drugs increasing as the level of systolic BP increased. Drugs blocking the renin-angiotensin system were most commonly prescribed, followed by calcium channel blockers. Lipid-lowering drugs and anticoagulant/antiplatelet agents were used in about 30% and 25% of patients, respectively.
CONCLUSIONS: Asian patients with type 2 diabetes had a high prevalence of MA and reduced kidney function. Furthermore, BP and HbA1c control was only achieved in a minority of patients. Aggressive risk management by administration of reno- and cardioprotective treatments is urgently needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18715217     DOI: 10.1089/dia.2007.0296

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  10 in total

1.  Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.

Authors:  Xilin Yang; Wing Yee So; Ronald C W Ma; Gary T C Ko; Alice P S Kong; Hailu Zhao; Andrea O Y Luk; Christopher W K Lam; Chung Shun Ho; Peter C Y Tong; Juliana C N Chan
Journal:  Diabetes Care       Date:  2009-07-10       Impact factor: 19.112

Review 2.  Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis.

Authors:  Edoardo Mannucci; Matteo Monami; Ilaria Dicembrini; Attilio Piselli; Massimo Porta
Journal:  J Endocrinol Invest       Date:  2014-04-04       Impact factor: 4.256

3.  Microalbuminuria in relation to the metabolic syndrome and its components in a Chinese population.

Authors:  Chang-Sheng Sheng; Bang-Chuan Hu; Wang-Xiang Fan; Jun Zou; Yan Li; Ji-Guang Wang
Journal:  Diabetol Metab Syndr       Date:  2011-04-07       Impact factor: 3.320

4.  The Incidence of Cardiovascular Events Is Comparable Between Normoalbuminuric and Albuminuric Diabetic Patients With Chronic Kidney Disease.

Authors:  Eunyoung Lee; Hyung Jung Oh; Jung Tak Park; Seung Hyeok Han; Dong-Ryeol Ryu; Shin-Wook Kang; Tae-Hyun Yoo
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

5.  Association between Urine Albumin-to-Creatinine Ratio within the Normal Range and Incident Hypertension in Men and Women.

Authors:  Dhananjay Yadav; Dae Ryong Kang; Sang Baek Koh; Jang Young Kim; Song Vogue Ahn
Journal:  Yonsei Med J       Date:  2016-11       Impact factor: 2.759

6.  The effects of AER and eGFR on outcomes of CVD in patients with T2DM in an urban community over 8 years of multifactorial treatment: the Beijing Communities Diabetes Study 18.

Authors:  Xue-Lian Zhang; Ming-Xia Yuan; Gang Wan; Guang-Ran Yang; Dong-Mei Li; Han-Jing Fu; Liang-Xiang Zhu; Rong-Rong Xie; Jian-Dong Zhang; Yu-Jie Lv; Yu-Ling Li; Xue-Ping Du; Zi-Ming Wang; Xue-Li Cui; De-Yuan Liu; Ying Gao; Shu-Yan Cheng; Qian Wang; Yu Ji; Guang-Wei Li; Shen-Yuan Yuan
Journal:  Ther Clin Risk Manag       Date:  2018-08-31       Impact factor: 2.423

7.  Plasma phenylalanine and tyrosine and their interactions with diabetic nephropathy for risk of diabetic retinopathy in type 2 diabetes.

Authors:  Hui-Huan Luo; Juan Li; Xiao-Fei Feng; Xiao-Yu Sun; Jing Li; Xilin Yang; Zhong-Ze Fang
Journal:  BMJ Open Diabetes Res Care       Date:  2020-09

8.  Spot urinary microalbumin concentration, metabolic syndrome and type 2 diabetes: Tehran lipid and glucose study.

Authors:  Zahra Gaeini; Zahra Bahadoran; Parvin Mirmiran; Reza Norouzirad; Asghar Ghasemi; Fereidoun Azizi
Journal:  BMC Endocr Disord       Date:  2022-03-08       Impact factor: 2.763

9.  Prevalence of microalbuminuria and associated electrocardiographic abnormalities in an Indo-Asian population.

Authors:  Tazeen H Jafar; Zeeshan Qadri; Shiraz Hashmi
Journal:  Nephrol Dial Transplant       Date:  2009-02-18       Impact factor: 5.992

10.  Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy.

Authors:  Xia Zou; Xiao-xi Zhang; Xin-yu Liu; Rong Li; Min Wang; Wei-jie Wu; Yi Sui; Hai-lu Zhao
Journal:  J Diabetes Res       Date:  2015-03-30       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.